ORIFARM AS

Org. no. 979996233 · OSLO · Founded 1998 · 9 employees

Score · fiscal year 2025

25of 100

How to read this: the company is ahead of 9 % of companies in the Morning class Medium in the same sector in 2025. What does this mean?

Rank in the Morning class Medium: 3,360 of 3,712 · What are Morning company classes?
Place in the whole sector: 20,066 of 23,059 · Handel

Profile

Beaver · Builder

Lower profitability, lower solidity

Position against comparable companies in 2025, not a verdict on the company. Based on profitability 38 and solidity 10 out of 100 among companies in the Morning class Medium in the same sector in 2025. Methodology

Against the sector

ORIFARM AS is 25 points below the median for companies in the Morning class Medium in the same sector in 2025.

Median score 50 among 3,712 companies.

Against companies in the Morning class Medium in the same sector in 2025: operating margin 1.2% (median 3.0%) and equity ratio 9.4% (median 30.0%).

Source: Register of Company Accounts and Central Coordinating RegisterFetched 28 October 2026Report an issue
Key figures · 2025

The numbers behind the score

The numbers behind the score · 2025
MeasureCompanyMedianAhead of
Operating revenue250 MNOK93 MNOK
Operating margin 1.2% 3.0% 29 %
Profit margin 1.3% 2.8% shown, not part of the index
Return on assets 10.5% 11.6% 46 %
Equity ratio 9.4% 30.0% 12 %
Debt-to-equity 9.67 2.24 9 %
Current ratio 0.90 1.39 6 %
Revenue growth −32.5% 6.1% 2 %
Revenue per employee27.81 MNOK5.07 MNOK

The median and “ahead of” refer to companies in the Morning class Medium in the same sector in 2025. The bar shows the share of companies the figure is ahead of.

With an index of 25, ORIFARM AS does better than 9% of companies in the Morning class Medium in the same sector (3,712 companies) in 2025.

Over time

Score 2023–2025

CompanyMedian0255075100202320242025
  • ORIFARM AS
  • Median: companies in the Morning class Medium in the same sector
Summary analysis

ORIFARM AS has a score of 25 for 2025, rank 20,066 of 23,059 in the sector.

Strongest: Consistency: percentile 66 against peers.

Weakest: Growth: percentile 2 against peers, revenue growth −32.5% against a median of 6.1%. Liquidity: percentile 6 against peers, current ratio 0.90 against a median of 1.39.

Worth a closer look

Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made

Analysis · 2025

What the numbers say

ORIFARM AS had an operating margin of 1.2% and an equity ratio of 9.4% in 2025, and ranks 20,066 of 23,059 in Handel.

From 2024 to 2025: revenue fell by 32% and the equity ratio fell from 21.1% to 9.4%.

This text is generated automatically from the 2025 accounts.

Estimated value · 2025

Three simple methods

The methods give between 4 MNOK and 24 MNOK.

MethodInputMultipleEstimate
P/E Net profit: 2.4 MNOK 10.0 24 MNOK
EV/EBIT Operating profit: 3.1 MNOK
minus net debt 0.4 MNOK
8.0 24 MNOK
P/B Equity: 4.3 MNOK 1.0 4 MNOK

A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation

Indications · 2025

Worth a closer look

  • watch

    The equity ratio is very low. Could the company absorb a bad year, and does it need more equity?

    Based on: Equity ratio 9.4% (median 30.0%).

  • watch

    Consider strengthening liquidity: current liabilities are 1.1 times current assets.

    Based on: Current ratio 0.90 (median 1.39).

Indications based on the latest annual accounts from open data. Not investment or financial advice.

Financial costs were 4.0% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.

See interest rates, prices and exchange rates for the sector

Data quality

No anomalies found in the figures.

Stress test · 2022

Scenario analysis: the sector's weakest year

We have no accounts for 2022, the sector's weakest year, for this company.

The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology

Components · 2025

What the score is made of

Profitability38 weight 30%
Solidity10 weight 25%
Liquidity6 weight 15%
Growth2 weight 15%
Consistency66 weight 15%

Durability: 25 (average over 3 years)

Index version 2. Data completeness 100%: the share of the weights that had data.

2025

Questions and answers

How profitable is ORIFARM AS?

The operating margin was 1.2% in 2025, against a median of 3.0% among companies in the Morning class Medium in the same sector. Return on assets was 10.5%.

How solid is ORIFARM AS?

The equity ratio was 9.4% in 2025 (median 30.0%). Debt-to-equity was 9.67 (median 2.24).

What is the liquidity of ORIFARM AS like?

The current ratio was 0.90 in 2025 (median 1.39). Current assets did not cover current liabilities.

How does ORIFARM AS compare in Handel?

ORIFARM AS ranks 20,066 of 23,059 in Handel for 2025. Among companies in the Morning class Medium it is number 3,360 of 3,712. Revenue changed by −32.5% from the year before.

Group accounts

The company is registered as part of a group, but we have no group accounts for it. Group accounts are filed by the parent company, and open data does not say which company that is.

Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.

We do not show the group structure, because open data does not say who owns whom.

From the Central Coordinating Register

Org. no.
979996233
Legal form
AS · part of a group
Sector
Handel (46.460)
Morning company class
Medium
Employees
9 registered 10 September 2026
Founded
24 June 1998 28 years in operation
Share capital
0.50 MNOK
Business address
Sandakerveien 138, 0484 OSLO
Municipality
Oslo rank 63–220 of 357 in Norway
Latest accounts filed
2025

Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre

Ownership and roles

Chief executive
Sverre Haugen
Chair of the board
Hans Carl Bøgh-Sørensen
Board member
Mads Fink Eriksen
Auditor
DELOITTE AS
Accountant
AZETS INSIGHT AS

Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.

Owners and shareholdings will appear here once the shareholder data extract is in place.

Coming · not built yet

Error in the data?

Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.

Report an issue

Figures last fetched 28 October 2026.

Details

Year by year · 2023–2025

Key figure202320242025Trend
Index173325
Rank19,02417,53120,066
Operating margin1.0%1.3%1.2%
Return on assets2.2%10.7%10.5%
Equity ratio10.5%21.1%9.4%
Current ratio1.061.040.90
Revenue growth–−7.8%−32.5%

Accounts

From the Brønnøysund Register Centre, in the company's reporting currency (NOK).

Key figure202320242025
Operating revenue402.2 MNOK370.7 MNOK250.3 MNOK
Operating profit4.1 MNOK4.6 MNOK3.1 MNOK
Profit before tax5.1 MNOK6.4 MNOK3.2 MNOK
Net profit3.9 MNOK4.9 MNOK2.4 MNOK
Financial expenses0.1 MNOK0.1 MNOK1.6 MNOK
Total assets231.7 MNOK60.9 MNOK45.7 MNOK
Current assets218.1 MNOK49.4 MNOK36.6 MNOK
Equity24.3 MNOK12.9 MNOK4.3 MNOK
Retained earnings17.7 MNOK6.3 MNOK–
Total liabilities207.4 MNOK48.0 MNOK41.4 MNOK
Current liabilities206.5 MNOK47.2 MNOK40.8 MNOK

Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 28 October 2026, accounts id 7105579.

Similar companies